Anfield Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Anfield Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.34K	Hold	3	–	–	﹤0.01%	612
2025 Q4	$1.36K	Hold	3	–	–	﹤0.01%	485
2025 Q3	$1.18K	Buy	+3	New	+$1.25K	﹤0.01%	505
2025 Q1	–	Sell	-2,977	Closed	-$1.2M	–	487
2024 Q4	$1.2M	Hold	2,977	–	–	0.44%	40
2024 Q3	$1.38M	Buy	+2,977	New	+$1.43M	0.53%	37
2024 Q2	–	Sell	-2,576	Closed	-$1.08M	–	535
2024 Q1	$1.08M	Buy	+2,576	New	+$1.09M	0.52%	49
2023 Q3	–	Sell	-2,604	Closed	-$916K	–	87
2023 Q2	$916K	Buy	+2,604	New	+$877K	0.4%	50
2023 Q1	–	Sell	-532	Closed	-$154K	–	92
2022 Q4	$154K	Sell	532 -711	-57%	-$217K	0.08%	69
2022 Q3	$360K	Buy	1,243 +43	+4%	+$12.4K	0.17%	61
2022 Q2	$338K	Buy	1,200 +172	+17%	+$46K	0.15%	62
2022 Q1	$268K	Buy	1,028 +588	+134%	+$140K	0.1%	68
2021 Q4	$97K	Buy	440 +400	+1,000%	+$77.8K	0.03%	80
2021 Q3	$7K	Buy	+40	New	+$7.81K	﹤0.01%	96

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Anfield Capital Management's VRTX Position: Q1 2026 in Review

Anfield Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 3 shares worth $1.34K. The position accounts for ﹤0.01% of the portfolio, ranked #612.

Anfield Capital Management first reported a position in VRTX in Q3 2021 and has held it in 13 quarters since. The position peaked at $1.38M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Anfield Capital Management held 3 shares of Vertex Pharmaceuticals worth $1.34K as of Q1 2026.
Anfield Capital Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
Vertex Pharmaceuticals made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #612 holding.
Anfield Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2021 and has held it in 13 quarters since.
Anfield Capital Management's Vertex Pharmaceuticals position peaked at $1.38M in Q3 2024.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.